VANDA PHARMACEUTICALS INC. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
VANDA PHARMACEUTICALS INC. (VNDA) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of $5.95 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2018-02-15
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2017 was $5.95M, a 935.30% increase from fiscal 2016.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2016 was $575.00K, a 93.90% decline from fiscal 2015.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2015 was $9.43M.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month |
|---|---|
| 2017-12-31 | $5.95M 10-K · filed 2018-02-15 |
| 2016-12-31 | $575.00K 10-K · filed 2018-02-15 |
| 2015-12-31 | $9.43M 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |